India  
 
NewsR.in

United States: FDA Approves Sandoz Denosumab Biosimilars - Goodwin Procter LLP

Mondaq Monday, 18 March 2024
On March 5, Sandoz announced that the FDA approved its denosumab biosimilars, WYOST and JUBBONTI, as interchangeable with Amgen's XGEVA and PROLIA.
0
shares		ShareTweetSavePostSend
 

You Might Like


Related news from verified sources

United States: FDA Approves First Cellular Therapy For Treatment Of Unresectable Or Metastatic Melanoma - Goodwin Procter LLP

 On February 16, 2024, the FDA approved Iovance's AMTAGVI, the first approved cellular therapy for the treatment of adult patients with unresectable or metastatic...
Mondaq